Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat:: Therapeutic potential for migraine

被引:85
作者
Peeters, Magali [1 ]
Gunthorpe, Martin J. [1 ]
Strijbos, Paul J. L. M. [1 ]
Goldsmith, Paul [1 ]
Upton, Neil [1 ]
James, Michael F. [1 ]
机构
[1] GlaxoSmithKline Inc, Neurol & Gastrointestinal Ctr Excellence Drug Dis, Harlow, Essex, England
关键词
D O I
10.1124/jpet.106.117101
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Spreading depression ( SD) has long been associated with the underlying pathophysiology of migraine. Evidence that the NmethylD- aspartate ( NMDA) glutamate receptor ( NMDA- R) is implicated in the generation and propagation of SD has itself been available for more than 15 years. However, to date, there are no reports of NMDA- R antagonists being developed for migraine therapy. In this study, an uncompetitive, pan- NMDA- R blocker, memantine, approved for clinical use, and two antagonists with selectivity for NMDA- R containing the NR2B subunit, ( 1S, 2S)- 1-( 4- hydroxyphenyl)- 2-( 4- hydroxy- 4- phenylpiperidino)1- propanol ( CP- 101,606) and (+/-)-( R*, S*)-alpha-(4- hydroxyphenyl)-beta methyl- 4-( phenylmethyl)- 1- piperidine propanol ( Ro 25- 6981), were investigated to assess their protective effects against SD in the rat. Under isoflurane anesthesia, d. c. potential and the related cortical blood flow and partial pressure of O-2 ( pO(2)) were recorded simultaneously at separate cortical sites. Drugs ( 1, 3, and 10 mg/ kg i. p.) were given 1 h or 30 min before KCl application to the brain surface. Core temperature and arterial pCO(2), pO(2), and pH measurements confirmed physiological stability. KCl induced 7.7 +/- 1.8 ( mean +/- S. D.) SD events with d. c. amplitude of 14.9 +/- 2.8 mV. Memantine and CP- 101,606 dose- dependently decreased SD event number ( to 2.0 +/- 1.8 and 2.3 +/- 2.9, respectively) and SD amplitude at doses relevant for therapeutic use. Ro 25- 6981 also decreased SD events significantly, but less effectively ( to 4.5 +/- 1.6), without affecting amplitude. These results indicate that NR2B- containing NMDA receptors are key mediators of SD, and as such, memantine- and NR2B- selective antagonists may be useful new therapeutic agents for the treatment of migraine and other SD- related disorders ( e. g., stroke and brain injury). Whether chronic, rather than acute, treatment may improve their efficacy remains to be determined.
引用
收藏
页码:564 / 572
页数:9
相关论文
共 43 条
[1]   A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate [J].
Afridi, SK ;
Matharu, MS ;
Lee, L ;
Kaube, H ;
Friston, KJ ;
Frackowiak, RSJ ;
Goadsby, PJ .
BRAIN, 2005, 128 :932-939
[2]   Spreading depression: Imaging and blockade in the rat neocortical brain slice [J].
Anderson, TR ;
Andrew, RD .
JOURNAL OF NEUROPHYSIOLOGY, 2002, 88 (05) :2713-2725
[3]   Suppression of cortical spreading depression in migraine prophylaxis [J].
Ayata, C ;
Jin, HW ;
Kudo, C ;
Dalkara, T ;
Moskowitz, MA .
ANNALS OF NEUROLOGY, 2006, 59 (04) :652-661
[4]   Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model [J].
Bolay, H ;
Reuter, U ;
Dunn, AK ;
Huang, ZH ;
Boas, DA ;
Moskowitz, MA .
NATURE MEDICINE, 2002, 8 (02) :136-142
[5]   Cortical hyperexcitability in migraine patients before and after sodium valproate treatment [J].
Bowyer, SM ;
Mason, KM ;
Moran, JE ;
Tepley, N ;
Mitsias, PD .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2005, 22 (01) :65-67
[6]   PHARMACOLOGICAL STUDIES WITH SK AND F-93944 (TEMELASTINE), A NOVEL HISTAMINE H-1-RECEPTOR ANTAGONIST WITH NEGLIGIBLE ABILITY TO PENETRATE THE CENTRAL-NERVOUS-SYSTEM [J].
BROWN, EA ;
GRIFFITHS, R ;
HARVEY, CA ;
OWEN, DAA .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (03) :569-578
[7]   Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: The evidence to date [J].
Bullock, R .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2006, 20 (01) :23-29
[8]  
Cammarata D, 2005, HEADACHE, V45, P820
[9]   The NMDA receptor NR2B subunit: A valid therapeutic target for multiple CNS pathologies [J].
Chazot, PL .
CURRENT MEDICINAL CHEMISTRY, 2004, 11 (03) :389-396
[10]   Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists [J].
Chazot, PL ;
Lawrence, S ;
Thompson, CL .
NEUROPHARMACOLOGY, 2002, 42 (03) :319-324